VistaGen Therapeutics, Inc.
VTGN
$2.11
$0.041.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -32.98% | 8.00% | 369.53% | 568.62% | 386.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.98% | 8.00% | 369.53% | 568.62% | 386.31% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -32.98% | 8.00% | 369.53% | 568.62% | 386.31% |
| SG&A Expenses | 30.03% | 34.68% | 21.80% | -4.94% | -20.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.21% | 27.00% | -15.19% | -42.27% | -44.85% |
| Operating Income | -55.86% | -27.44% | 17.94% | 44.29% | 46.80% |
| Income Before Tax | -47.50% | -11.50% | 28.42% | 50.44% | 49.67% |
| Income Tax Expenses | 142.86% | 142.86% | -57.14% | -25.00% | -36.36% |
| Earnings from Continuing Operations | -47.51% | -11.52% | 28.43% | 50.44% | 49.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.51% | -11.52% | 28.43% | 50.44% | 49.66% |
| EBIT | -55.86% | -27.44% | 17.94% | 44.29% | 46.80% |
| EBITDA | -56.02% | -27.51% | 17.98% | 44.38% | 46.89% |
| EPS Basic | 56.13% | 72.42% | 76.75% | 75.09% | 61.94% |
| Normalized Basic EPS | 56.13% | 72.43% | 76.75% | 75.10% | 61.94% |
| EPS Diluted | 56.08% | 72.38% | 76.72% | 75.07% | 61.94% |
| Normalized Diluted EPS | 56.13% | 72.43% | 76.75% | 75.10% | 61.94% |
| Average Basic Shares Outstanding | 127.10% | 285.39% | 255.50% | 177.66% | 95.71% |
| Average Diluted Shares Outstanding | 127.10% | 285.39% | 255.50% | 177.66% | 95.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |